SANTA CRUZ BIOTECHNOLOGY, INC.

PDC-E2 (N-20): sc-16890



BACKGROUND

Primary biliary cirrhosis (PBC) is a chronic, destructive autoimmune liver disease characterized by the presence of antimitochondrial autoantibodies in patient's serum and T cell-mediated destruction of the biliary epithelial cells lining the small intrahepatic bile ducts. Patient sera are characterized by a high frequency (greater than 95%) of autoantibodies directed to a mitochondrial antigen, identified as the E2 component of the pyruvate dehydrogenase multienzyme complex (PDC-E2). PDC-E2 contains both an amino-terminal lipoyl-bearing domain and a carboxy-terminal catalytic domain. The human sequence preserves the Glu-Thr-Asp-Lys-Ala motif of the lipoyl-bearing site. Two conformationally alternative forms of the PDC-E2 protein have been revealed by immunoblotting. The immunodominant autoepitopes of the autoantigens correspond to the inner lipoyl domain. A significant number of asymptomatic patients found to have antibodies to PDC-E2 are at high risk of developing primary biliary cirrhosis.

CHROMOSOMAL LOCATION

Genetic locus: DLAT (human) mapping to 11q23.1; Dlat (mouse) mapping to 9 A5.3.

SOURCE

PDC-E2 (N-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of PDC-E2 of human origin.

PRODUCT

Each vial contains 200 μg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-16890 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

PDC-E2 (N-20) is recommended for detection of PDC-E2 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

PDC-E2 (N-20) is also recommended for detection of PDC-E2 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for PDC-E2 siRNA (h): sc-40813, PDC-E2 siRNA (m): sc-40814, PDC-E2 shRNA Plasmid (h): sc-40813-SH, PDC-E2 shRNA Plasmid (m): sc-40814-SH, PDC-E2 shRNA (h) Lentiviral Particles: sc-40813-V and PDC-E2 shRNA (m) Lentiviral Particles: sc-40814-V.

Molecular Weight of PDC-E2: 70 kDa.

Positive Controls: PDC-E2 (m): 293T Lysate: sc-122447, HeLa whole cell lysate: sc-2200 or PDC-E2 (h): 293T Lysate: sc-114530.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA





 PDC-E2 (N-20): sc-16890. Western blot analysis
 PDC-E:

 of PDC-E2 expression in non-transfected 2931:
 sc-11752 (A), human PDC-E2 transfected 2937:
 and m

 sc-114750 (B) and HeLa (C) whole cell lysates.
 whole
 whole



PDC-E2 expression in non-transfected: sc-11752 (**A**) and mouse PDC-E2 transfected: sc-122447 (**B**) 293T whole cell lysates.



PDC-E2 (N-20): sc-16890. Immunofluorescence staining

of methanol-fixed KNRK cells showing cytoplasmic

PDC-E2 (N-20): sc-16890. Western blot analysis of PDC-E2 expression KNRK whole cell lysate ($\bf A$), rat kidney ($\bf B$) and mouse liver ($\bf C$) extracts.

SELECT PRODUCT CITATIONS

 Bellucci, R., et al. 2007. Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood 109: 2001-2007.

localization

 Ijiri, T.W., et al. 2011. Identification and validation of mouse sperm proteins correlated with epididymal maturation. Proteomics 11: 4047-4062.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed

Try PDC-E2 (B-2): sc-271534 or PDC-E2 (C-9): sc-271352, our highly recommended monoclonal aternatives to PDC-E2 (N-20).